No beneficial effects seen for cyclosporine A in reperfused MI

January 28, 2016

(HealthDay)—A single intravenous cyclosporine A (CsA) bolus just before primary percutaneous coronary intervention has no beneficial effects on ST-segment resolution in reperfused myocardial infarction (MI), according to a study published in the Feb. 2 issue of the Journal of the American College of Cardiology.

Filippo Ottani, M.D., from the Ospedale GB Morgagni in Forli, Italy, and colleagues examined the effect of CsA on ST-segment resolution. Patients (age 63 ± 12 years) from 31 cardiac care units, with large ST-segment elevation MI and Thrombolysis In Myocardial Infarction flow grade 0 to 1 in the infarct-related artery, were randomized to 2.5 mg/kg intravenous CsA (207 ) or control (203 patients) before .

The researcher found that 52.0 percent of CsA patients and 49.0 percent of controls had ST-segment resolution ≥70 percent (P = 0.55). On day four, the median high-sensitivity cardiac troponin T (hs-cTnT) was 2,160 and 2,063 ng/L in the CsA and control group, respectively (P = 0.85). There was no between-group difference in left ventricular (LV) ejection fraction on day four and at six months. The site of infarct did not affect CsA efficacy. No acute allergic reactions were seen, or nonsignificant excesses of six-month mortality (5.7 versus 3.2 percent; P = 0.17) or cardiogenic shock (2.4 versus 1.5 percent; P = 0.33).

"In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial, a single intravenous CsA bolus just before primary percutaneous coronary intervention had no effect on ST-segment resolution or hs-cTnT, and did not improve clinical outcomes or LV remodeling up to six months," the authors write.

One author disclosed financial ties to the pharmaceutical and medical device industries. The CYCLE trial was partially funded by Novartis Italy. Reagents for measuring hs-cTnT were provided by Roche Diagnostics.

Explore further: Cyclosporine does not improve outcomes after PCI

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Cyclosporine does not improve outcomes after PCI

August 30, 2015
The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation ...

Pharmacoinvasive STEMI strategy best for smokers, nonsmokers

October 27, 2014
(HealthDay)—For patients with ST-segment elevation myocardial infarction, a pharmacoinvasive strategy after fibrinolysis is beneficial for smokers and nonsmokers, according to a study published in the Oct. 1 issue of The ...

White blood cell count predicts infarct size in STEMI

December 19, 2013
(HealthDay)—For patients with anterior wall ST-segment elevated myocardial infarction (STEMI), elevated white blood cell count (WBCc) on presentation is associated with increased infarct size, according to a study published ...

Cardiac prognosis bright for STEMI survivors post-PCI

November 11, 2014
(HealthDay)—Patients who survive the first month after an ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) have

Nonalcoholic fatty liver disease predicts MACE in STEMI

November 30, 2015
(HealthDay)—For patients without diabetes with ST-segment myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), nonalcoholic fatty liver disease (FLD) independently predicts impaired ...

Early invasive strategy no benefit 10 years after NSTE-ACS

July 29, 2015
(HealthDay)—For patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), routine early invasive strategy (coronary arteriography and myocardial revascularization, as clinically indicated) is not associated ...

Recommended for you

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Can a common heart condition cause sudden death?

September 20, 2018
About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions ...

New drugs could reduce risk of heart disease when added to statins

September 20, 2018
New drugs that lower levels of triglycerides (a type of fat) in blood could further reduce the risk of heart attack when added to statins. These new drugs, which are in various stages of development, could also reduce blood ...

Mediterranean-style diet may lower women's stroke risk

September 20, 2018
Following a Mediterranean-style diet may reduce stroke risk in women over 40 but not in men—according to new research led by the University of East Anglia.

Inflammation critical for preventing heart attacks and strokes, study reveals

September 19, 2018
Inflammation, long considered a dangerous contributor to atherosclerosis, actually plays an important role in preventing heart attacks and strokes, new research from the University of Virginia School of Medicine reveals.

People who walk just 35 minutes a day may have less severe strokes

September 19, 2018
People who participate in light to moderate physical activity, such as walking at least four hours a week or swimming two to three hours a week, may have less severe strokes than people who are physically inactive, according ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.